EP0526905A2 - Multimères des formes solubles des récepteurs TNF, leurs préparation et compositions pharmaceutiques les contenant - Google Patents

Multimères des formes solubles des récepteurs TNF, leurs préparation et compositions pharmaceutiques les contenant Download PDF

Info

Publication number
EP0526905A2
EP0526905A2 EP92113463A EP92113463A EP0526905A2 EP 0526905 A2 EP0526905 A2 EP 0526905A2 EP 92113463 A EP92113463 A EP 92113463A EP 92113463 A EP92113463 A EP 92113463A EP 0526905 A2 EP0526905 A2 EP 0526905A2
Authority
EP
European Patent Office
Prior art keywords
tnf
multimer
soluble
receptors
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP92113463A
Other languages
German (de)
English (en)
Other versions
EP0526905A3 (en
EP0526905B1 (fr
Inventor
David Wallach
Cord Brakebusch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11062796&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0526905(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of EP0526905A2 publication Critical patent/EP0526905A2/fr
Publication of EP0526905A3 publication Critical patent/EP0526905A3/en
Application granted granted Critical
Publication of EP0526905B1 publication Critical patent/EP0526905B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • the present invention relates to multimers of the soluble forms of the tumor necrosis factor receptors, their preparation and pharmaceutical compositions containing them.
  • Tumor necrosis factor is a cytokine produced by a number of cell types, primarily by mononuclear phagocytes. At present, two different TNFs have been identified: TNF-a and TNF-,8 - (lymphotoxin). Both TNF-a and TNF-,8 initiate their effects by binding to specific cell surface receptors.
  • TNF-a and TNF-,8 are known to exert both beneficial as well as deleterious effects on a number of different target cells involved in the inflammatory response.
  • TNF for example, stimulates the growth of fibroblasts and induces in these cells the synthesis of collagenase, prostaglandin E2 and IL-6.
  • TNF also decreases in adipocytes the activity of lipoprotein lipase, activates osteoclasts and increases in endothelial cells adhesivity for blood leukocytes.
  • TNF-a is known to be a major cause for the symptoms of septic shock.
  • TNF may cause excessive loss of weight (cachexia) by suppressing activities of adipocytes and by causing anorexia (TNF-a was therefore called cachectin).
  • cachectin anorexia
  • TNF initiates its function by binding to specific cell surface receptors.
  • TNF-R TNF receptors
  • p55-TNF receptor the p55-TNF receptor and the p75-TNF receptor
  • TBP-I and TBP-II Two proteins called TBP-I and TBP-II which bind specifically to TNF have been shown to cross-react immunologically with the two receptors. Both proteins provide protection against the in vitro cytocidal effect of TNF and both bind TNF-,8 less effectively than TNF-a.
  • TBP-I and TBP-II were found to be fully identical to sequences found in the extra-cellular domains of the cell-surface receptors, but do not contain any part of the intracellular domain of the receptors.
  • TBP-I and TBP-II reflects the conservation, in TBP-I and TBP-II, of part of the structural features of the cell surface TNF-Rs, which are important for binding of TNF by the receptors and the initiation of cell response to TNF thereby. Due to this conservation of structure, TBP-I and TBP-II have the ability to compete with the cell surface TNF-Rs for TNF and thus block its function.
  • TNF in its natural state, exists as a multimer (trimer) consisting of three identical polypeptide chains, each with a molecular size of about 17,000 D.
  • TNF To elicit its effects, TNF must bind to the TNF Receptors in its trimeric form. Although the TNF monomer also binds to cells (but at a lower affinity when compared with the TNF trimer), it has no effect.
  • the present invention now provides multimers of the soluble forms of the TNF-Rs, and salts or functional derivatives thereof. These multimers, effectively interfere with the binding of TNF to the cell-surface receptors and thus do not allow TNF to exert its deleterious effect.
  • multimers refers to any combination of monomers held together, for example, by covalent bonding, liposome formation, the incorporation of monomers of the soluble form of TNF-R into a single recombinant molecule, or any other combination of monomers.
  • the multimers may either be in dimeric, trimeric or other multimeric form and may comprise, for example, TBP-I, TBP-II, or mixtures thereof.
  • the invention also provides methods of producing these multimers by covalent cross-linking of the soluble forms of the TNF-Rs.
  • the present invention relates to DNA molecules comprising the nucleotide sequences encoding the multimers of the soluble forms of the TNF-Rs, to expression vehicles comprising them, to host cells transformed therewith, and to processes for producing the multimers by culturing the transformed cells in a suitable culture medium.
  • the invention also relates to DNA molecules which hybridize to the above DNA molecules and which code for a multimer of the soluble forms of the TNF-Rs, or a funtional derivative thereof.
  • the term "functional derivatives" is defined hereinafter.
  • the multimers according to the invention, and the salts and functional derivatives thereof, may comprise the active ingredient of pharmaceutical compositions for protecting mammals from the deleterious effects of TNF. These compositions are yet another aspect of the present invention.
  • TNF exists and exerts its biological action as a trimer.
  • TNF-Rs to which TNF binds, i.e. whether the TNF trimer binds to individual molecules of the TNF-Rs, or the receptors themselves also exist as multimers or become multimers following TNF binding which better accomodates the TNF trimers.
  • TNF-Rs exist in aggregated forms in cells exposed to TNF.
  • TNF-Rs This was shown by analysis of full-length and C-terminal truncated forms of the human p55-TNF-Rs tagged by cross-linking to labelled TNF.
  • Radiolabelled TNF was applied on these cells and cross-linked chemically to the TNF-Rs.
  • the TNF-Rs were solubilized with a detergent, and antibodies specific to the human receptors were applied to immunoprecipitate the human receptors, examining thereby whether murine receptors associate noncovalenty with the human receptor as a consequence of aggregation of the receptors.
  • TBP-I and TBP-II monomers must be administered in very high doses in order to result in effective inhibition of TNF-binding to cells in the human body.
  • the multimers of the soluble forms of TNF-Rs according to the invention are believed to be more effective in inhibiting TNF activity at lower doses, since they can effectively compete with the TNF trimers for the binding sites on the aggregates of the cell surface TNF-Rs.
  • the multimers of the soluble forms of the TNF-Rs may be produced chemically by using known methods which will result in the formation of either dimers or higher multimers of the soluble forms of the TNF-Rs.
  • Another way of producing the multimers of the soluble forms of the TNF-Rs is by recombinant techniques. In this way, massive production of multimers with optimal TNF binding activity will be made possible.
  • compositions containing the multimers of the soluble forms of the TNF-Rs may be employed for antagonizing the deleterious effects of TNF in mammals, i.e. they serve for treating conditions where excess of TNF is either endogenously formed or exogenously administered.
  • compositions comprise the multimers of the soluble forms of the TNF-Rs according to the invention, or their salts or functional derivatives as their active ingredient.
  • the pharmaceutical compositions are indicated for any condition of excess TNF, either endogenously produced, such as in septic shock, cachexia, graft-versus-host reactions, autoimmune diseases such as rheumatoid arthritis, and the like, or exogenously administered, i.e. administration of overdoses of TNF.
  • salts refers to both salts of carboxyl groups and to acid addition salts of amino groups of the protein molecule.
  • Salts of a carboxyl group may be formed by means known in the art and include inorganic salts, for example, sodium, calcium, ammonium, ferric or zinc salts and the like, and salts with organic bases as those formed, for example, with amines, such as triethanolamine, arginine or lysine, piperidine, procaine and the like.
  • Acid addition salts include, for example, salts with mineral acids such as for example, hydrochloric acid or sulfuric acid, and salts with organic acids such as, for example, acetic acid or oxalic acid.
  • “Functional derivatives” as used herein covers derivatives which may be prepared from the functional groups which occur as side chains on the residues or the N- or C-terminal groups, by means known in the art, and are included in the invention as long as they remain pharmaceutically acceptable, i.e. they do not destroy the activity of the protein and do not confer toxic properties on compositions containing it.
  • These derivatives may, for example, include aliphatic esters of the carboxyl groups, amides of the carboxyl groups by reaction with ammonia or with primary or secondary amines, N-acyl derivatives of free amino acid groups of the amino acid residues formed with acyl moieties (e.g. alkanoyl or carboxyclic aroyl groups) or O-acyl derivatives of free hydroxyl group (for example that of seryl or threonyl residues) formed with acyl moieties.
  • acyl moieties e.g. alkanoyl or carboxyclic aroyl groups
  • O-acyl derivatives of free hydroxyl group for example that of seryl or threonyl residues
  • “Functional derivatives” also comprise multimers made up of soluble forms of TNF-Rs in which changes have been introduced in the sequence of the amino acids making up the soluble TNF-Rs by any conventional method. These changes may comprise elongation or truncation of the soluble TNF-R molecule or deletion or replacement of one or more amino acids making up the soluble TNF-R. It is understood that none of the above changes may affect the biological properties of the TNF-Rs.
  • compositions according to the invention are administered depending on the condition to be treated, via the accepted ways of administration. For example, in the case of septic shock, intravenous administration will be preferred, while in the case of arthritis, local injection may be indicated.
  • the pharmaceutical compositions may also be administered continuously, i.e. by way of infusion, or orally.
  • the formulation and dose will depend on the condition to be treated, the route of administration and the condition and the body weight of the patient to be treated. The exact dose will be determined by the attending physician.
  • compositions according to the invention are prepared in the usual manner, for example by mixing the active ingredient with pharmaceutically and physiologically acceptable carriers and/or stabilizers and/or excipients, as the case may be, and are prepared in dosage form, e.g. by lyophilization in dosage vials.
  • the pharmaceutical composition comprises a liposome composition
  • the latter is adjusted so as to assure optimal interaction of the liposome with phagocytic cells, optimal accessibility of the liposomes to the circulation and/or other compartments in the body, and optimal rates of clearance of the liposomes from those compartments.
  • Figures 1A and 1B show the different receptor sizes after covalent cross-linking with labelled TNF, immunoprecipitation and SDS-PAGE analysis. The patterns shown are as follows:
  • EXAMPLE 1 Detection of aggregates of human TNF-Rs in the analysis of their sizes
  • A9 cells, as well as cells expressing the wild type and mutant forms of the human p55-TNF-R, and HeLa cells were detached by incubation in PBS containing 5mM EDTA and, after rinsing with binding buffer, were suspended in aliquots of 5X10 7 cells in 1 ml binding medium, containing radiolabelled TNF. After incubation with occasional shaking for 4 hrs. on ice, the cells were washed once with Dulbecco's balanced salt solution (PBS+) and incubated for 20 min. in the same buffer containing 1 mM bis(sulfosuccinimidyl)-suberate (Pierce).
  • Cross-linking was stopped by adding Tris-HCI and glycine-HCI, pH 7.4 (both to a final concentration of 100nM) followed by two washes with PBS+.
  • the cells were then extracted for 1 hr. at 4°C, using 600 ⁇ l of a lysis buffer containing 20 mM Hepes, pH 7.4, 150mM NaCI, 1 % deionised Triton X-100, 1 ⁇ g/ml leupeptin and 1 mM-phenylmethylsulfonyl fluoride. After centrifugation for 30 min. at 10.000xg the cell extracts were divided into two equal portions.
  • portion A was acidified by adding 90 ⁇ l 1 M glycine-HCI bufer pH 2.5 and, after 1 hr. incubation on ice, neutralized with 30 ⁇ l 1 M NaOH.
  • monoclonal antibodies against the human p55-TNF-R were added.
  • 20 ⁇ l protein-A Sepharose beads (Pharmacia) equilibrated with PBS + . were added and, following 60 min. incubation at 4°C, washed three times with the lysis buffer containing 2M KCI, and two times with PBS.
  • the beads were resuspended in 15 ⁇ l sample buffer containing 4% (w/v) SDS and 6% (v/v) ⁇ -mercaptoethanol and boiled for 3 min. The supernatant was analysed by SDS-PAGE (10% polyacrylamide) followed by autoradiography.
  • Figs. 1A and 1B the receptors for TNF exist in aggregated forms in cells exposed to TNF.
  • These figures present the SDS-PAGE analysis of the full-length and truncated forms of the human p55-TNF-Rs (see the schematic representation of the different forms in Fig. 2) expressed in murine A9 cells and tagged by applying radio-labelled TNF on the cells followed by cross-linking.
  • the receptors were immunoprecipitated from detergent extracts of the cells following acidification of the extracts, in order to dissociate non-covalent aggregates of proteins (A) or without such acidification (B).
  • Mr molecular weight markers
  • Labelled bands whose sizes correspond to the expressed human receptors, tagged by cross-linking to either one or to two labelled TNF molecules, are denoted with solid arrows (sizes of 72 and 89 kD for the full length receptor, 59 and 76 kD for the A:310-426 human p55-TNF-R, 51 and 68 kD for the A:244-426 human p55-TNF-R and 48 and 65 kD for the A:215:426 human p55-TNF-R).
  • the labelled bands whose sizes correspond to the full-length murine receptors, cross-linked either to one or to two TNF molecules (72 and 89 kD) are denoted with empty arrows, and the bands which correspond to cross-linked monomers, dimers and trimers of TNF (17, 34 and 51 kilodaltons) - by stippled lines.
  • the antibodies applied for immunoprecipitation in this analysis of the receptor size recognized specifically the receptors of human origin (solid arrows). These antibodies did not precipitate TNF receptors from extracts of non-transfected A9 cells (compare lanes 1 and 2). However, in application of these antibodies to extracts of the A9 cells which express the human p55-TNF-R, it was found that, together with the human receptors, the antibodies precipitated also some of the murine receptors, which were easily distinguishable from the truncated human receptors by their full length size (empty arrows) (lanes 3-6 in Fig. 1 B), implying that the TNF receptors exist in the cells as aggregates, containing both receptors of human and of murine origin.
  • Site directed mutagenesis of this shortened form of the cDNA was carried out using the "Altered Sites" (mutagenesis) kit of Promega. Stop codons were introduced in the following points: After leucine 309 (mutant A:310-426) using the oligonucleotide:
  • DMEM Dulbecco's Minimal Essential Medium
  • the expression constructs encoding the wild type and the mutant receptors were cotransfected together with the neomycin resistance conferring plamsid pSV2neo into these cells, using the calcium phosphate precipitation method. After 10 to 14 days selection in growth medium containing 500 ⁇ g/ml G418, resistant colonies were isolated and checked for expression of the human p55 TNF-R by measuring TNF binding to the cells.
  • Figure 2 illustrates the structure of the wild type human p55-TNF-receptor. It consists of icons depicting the full length human p55-TNF-R and the truncated forms of this receptor created by site-directed mutagenesis. Using these oligonucleotides, stop codons were introduced into the intracellular domain of the receptor at amino acids 310 (the A:310-426 human p55-TNF-R mutant), 244 (the ⁇ :244-426 human p55-TNF-R mutant), and 215 (the A:215:426 human p55-TNF-R mutant).
  • Figs. 3 and 4 provide further evidence for the existence of the cell-surface TNF-R as aggregates as well as for two other points, namely that aggregation of functional receptors is necessary for the activity of these receptors, as well as that involvement of non-functional receptors in this aggregation results in effective inhibition of TNF function.
  • Fig. 3 illustrates the cytocidal effects of TNF (A) and of monoclonal antibodies against the human p55-TNF-R (B) in A9 cells, in A9 cells expressing the full length human p55-TNF-R, and in A9 cells expressing the cytoplasmic deletion mutants of the human p55-TNF-R (the :310-426 human p55-TNF-R, the :244-426 human p55-TNF-R, and the :215:426 human p55-TNF-R.
  • FIG. 4 the cytocidal effect of TNF, applied together with CHI (50 ⁇ g/ml) to A9 cells (A), A9 cells expressing the A:310-426 human p55-TNF-R (B) and A9 cells expressing the A:215:426 human p55-TNF-R (C), was examined in the presence and absence of antibodies to the human p55-TNF-R. Similar sensitization by the antibodies to the cytocidal effect of TNF was observed in A9 cells expressing the A:244-426 human p55-TNF-R mutant.
  • the antibodies had no effect at all in cells expressing any of the three truncated forms of the receptor, suggesting that these truncated forms are not functional. Furthermore, testing the effect of TNF itself on the cells revealed that, in contrast to the full-length human p55-TNF-R receptors, whose expression results in increased sensitivity of the A9 cells to TNF, the truncated forms of the receptors conveyed a decreased reponsiveness to the cytocidal effect of TNF.
  • EXAMPLE 3 Creation of multimers of the soluble forms of TNF-Rs by chemical cross-linking of these proteins
  • Procedure I Samples of the soluble forms of either the human p55- or the human p75-TNF-R are incubated with cysteine amide, or alternatively, with Biotin amide and with carboxypeptidase Y. In the presence of excess of the cysteine amide or the Biotin amide the enzymatic reaction leads primarily to incorporation to these compounds to the C-termini of the soluble receptors.
  • Procedure II The reactions are carried out as above, except that the amino acid within the receptor chosen to be the C-terminal for the soluble receptors is lysine and that lysine endopeptidase is applied instead of carboxypeptidase. Use of this enzyme assures that, beside removal of a single amino acid from the C-terminus of the soluble receptor, no further truncation of the soluble receptor takes place.
  • Receptors to whose C-termini cysteins were introduced as described above, are cross-linked to form dimers, using activated linkers of either one of the following two formulae:
  • Linkers of different lengths can be employed. The function of the products will be compared to each other and thus the optimal linker length will be defined. In case free cysteines turn out to be present within the soluble receptors, they will be blocked before the introduction of cysteine to the C-termini, by way of alkylation.
  • the soluble receptors to whose C-termini Biotin was introduced, as described above, are cross-linked with Avidin.
  • Each Avidin contains four Biotin binding sites. In that way tetramers of the receptors are formed.
  • part of the four binding sites in the Avidin serve for binding other proteins to which Biotin was linked.
  • several Avidin molecules are linked to each other, resulting in formation of higher aggregates of the soluble forms of the human TNF-Rs.
  • This approach allows also the binding of additional molecules to the soluble forms of the TNF-Rs (e.g. Fc portions of antibodies).
  • Avidin may be replaced with Streptavidin, the procedure itself remaining the same.
  • Such multimers of TNF receptors are formed by linking the molecules of soluble forms of the TNF-Rs to each other using cross-linking reagents specific to amine groups or to thiols. (The latter following partial reduction of the cysteins in the soluble receptors with ,8-mercapthoethanol or dithiothreitol).
  • Procedure I Liposomes expressing any Biotin-containing protein on their surface can be applied for that purpose. Soluble forms of the TNF-Rs to whose C-termini Biotin was linked, are linked to these liposomes with the use of (the tetravalent) Avidin.
  • TNF receptors truncated in the intracellular domains, but containing the transmembrane domains, are produced as described in Example 2. They are then incorporated into liposomes by dissociation in detergents, followed by their reconstitution in the presence of lipids by removal of the detergents.
  • Preparations of soluble receptor dimers or multimers are fractionated chromatographically, and fractions showing highest inhibitory effects on TNF function are further analyzed, to define the structures optimal for TNF inhibition.
  • affinity purification of the optimal inhibitors is performed, by applying preparations of soluble receptor dimers or multimers to TNF-affinity columns.
  • EXAMPLE 4 Creation of recombinant DNA molecules comprising nucleotide sequences coding for the multimers of the soluble TNF-Rs and their expression
  • the dimers and higher multimers of the soluble receptors can also be prepared by genetic engineering techniques and their preparation encompasses all the tools used in these techniques.
  • DNA molecules are provided which comprise the nucleotide sequence coding for such dimers or oligomers. These DNA molecules can be genomic DNA, cDNA, synthetic DNA and a combination thereof.
  • DNA molecules coding for a dimer of soluble receptors is carried out by ligating the cDNA sequence encoding the soluble form of a TNF-R to a sequence encoding a linker peptide and then further to a synthetic polynucleotide encoding the translation of the soluble receptor in the reverse orientation - from the original C-terminus to the N-terminus and lacking the sequence of the leader peptide.
  • Polymeric forms of the soluble receptors can be created, as mentioned above, by forming recombinant truncated receptors, deficient of intracellular domains but containing transmembrane domains, and incorporating them, by membrane reconstitution techniques, into liposomes.
  • Expression of the recombinant proteins can be effected in eukaryotic cells, bacteria or yeasts, using the appropriate expression vectors. Any method known in the art may be employed.
  • the DNA molecules coding for the multimers of the soluble forms of the TNF-Rs obtained by the above methods are inserted into appropriately constructed expression vectors by techniques well known in the art (see Maniatis et al., op cit.). Double-stranded cDNA is linked to plasmid vectors by homopolymeric tailing or by restriction linking involving the use of synthetic DNA linkers or blunt-ended ligation techniques. DNA ligases are used to ligate the DNA molecules and undesirable joining is avoided by treatment with alkaline phosphatase.
  • an expression vector should comprise also specific nucleotide sequences containing transcriptional and translational regulatory information linked to the DNA coding for the desired protein in such a way as to permit gene expression and production of the protein.
  • RNA polymerase a promoter recognizable by RNA polymerase, to which the polymerase binds and thus initiates the transcription process.
  • promoters There are a variety of such promoters in use, which work with different efficiencies (strong and weak promoters). They are different for prokaryotic and eukaryotic cells.
  • the promoters that can be used in the present invention may be either constitutive, for example, the int promoter of bacteriophage x, the bla promoter of the ,8-lactamase gene of pBR322, and the CAT promoter of the chloramphenicol acetyl transferase gene of pPR325, etc., or inducible, such as the prokaryotic promoters including the major right and left promoters of bacteriophage X (P L and P R ), the trp, recA, lacZ, lacl, ompF and gal promoters of E. coli, or the trp-lac hybrid promoter, etc. (Glick, B.R. (1987) J. Ind. Microbiol. :277-282).
  • ribosome-binding sites to ensure that the mRNA is efficiently translated.
  • SD sequence Shine-Dalgarno sequence
  • transcriptional and translational regulatory sequences may be employed, depending on the nature of the host. They may be derived from viral sources, such as adenovirus, bovine papilloma virus, Simian virus, or the like, where the regulatory signals are associated with a particular gene which has a high level of expression. Examples are the TK promoter of Herpes virus, the SV40 early promoter, the yeast ga14 gene promoter, etc. Transcriptional initiation regulatory signals may be selected which allow for repression and activation, so that expression of the genes can be modulated.
  • the DNA molecule comprising the nucleotide sequence coding for the TNF multimers of the invention and the operably linked transcriptional and translational regulatory signals is inserted into a vector which is capable of integrating the desired gene sequences into the host cell chromosome.
  • the cells which have stably integrated the introduced DNA into their chromosomes can be selected by also introducing one or more markers which allow for selection of host cells which contain the expression vector.
  • the marker may provide for prototrophy to an auxotropic host, biocide resistance, e.g., antibiotics, or heavy metals, such as copper, or the like.
  • the selectable marker gene can either be directly linked to the DNA gene sequences to be expressed, or introduced into the same cell by co-transfection.
  • Additional elements may also be needed for optimal synthesis of single chain binding protein mRNA. These elements may include splice signals, as well as transcription promoters, enhancers, and termination signals. cDNA expression vectors incorporating such elements include those described by Okayama, H., (1983) Mol. Cel. Biol. 3:280.
  • the introduced DNA molecule will be incorporated into a plasmid or viral vector capable of autonomous replication in the recipient host.
  • Factors of importance in selecting a particular plasmid or viral vector include: the ease with which recipient cells that contain the vector may be recognized and selected from those recipient cells which do not contain the vector; the number of copies of the vector which are desired in a particular host; and whether it is desirable to be able to "shuttle" the vector between host cells of different species.
  • Preferred prokaryotic vectors include plasmids such as those capable of replication in E. coli, for example, pBR322, CoIE1, pSC101, pACYC 184, etc. (see Maniatis et al., Molecular Cloning: A Laboratory Manual, op.cit.); Bacillus plasmids such as pC194, pC221, pT127, etc. (Gryczan, T., The Molecular Biology of the Bacilli, Academic Press, NY (1982), pp. 307-329); Streptomyces plasmids including pIJ101 (Kendall, K.J. et al., (1987) J. Bacteriol.
  • Streptomyces bacteriophages such as 0C31 (Chater, K.F. et al., in: Sixth International Symposium on Actinomycetales Biology, Akademiai Kaido, Budapest, Hungary (1986), pp. 45-54), and Pseudomonas plasmids (John, J.F., et al. (1986) Rev. Infect. Dis. 8:693-704), and lzaki, K. (1978) Jpn. J. Bacteriol. 33:729-742).
  • Preferred eukaryotic plasmids include BPV, vaccinia, SV40, 2-micron circle, etc., or their derivatives.
  • Such plasmids are well known in the art (Botstein, D., et al. (1982) Miami Wint. Symp. 19:265-274; Broach, J.R., in: The Molecular Biology of the Yeast Saccharomyces: Life Cycle and Inheritance, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, pp. 445-470 (1981); Broach, J.R., (1982) Cell 28:203-204; Bollon, D.P., et al. (1980) J. Clin. Hematol. Oncol. 10:39-48; Maniatis, T., in: Cell Biology: A Comprehensive Treatise. Vol. 3: Gene Expression, Academic Press, NY, pp. 563-608 (1980)).
  • the DNA construct(s) may be introduced into an appropriate host cell by any of a variety of suitable means: transformation, transfection, conjugation, protoplast fusion, electroporation, calcium phosphate-precipitation, direct microinjection, etc.
  • Host cells to be used in this invention may be either prokaryotic or eukaryotic.
  • Preferred prokaryotic hosts include bacteria such as E. coli, Bacillus, Streptomyces, Pseudomonas, Salmonella, Serratia, etc.
  • the most preferred prokaryotic host is E. coli.
  • Bacterial hosts of particular interest include E. coli K12 strain 294 (ATCC 31446), E. coli X1776 (ATCC 31537), E. coli W3110 (F-, lambda-, prototropic (ATCC 27325)), and other enterobacterium such as Salmonella typhimurium or Serratia marcescens and various Pseudomonas species. Under such conditions, the protein will not be glycosylated.
  • the prokaryotic host must be compatible with the replicon and control sequences in the expression plasmid.
  • Preferred eukaryotic hosts are mammalian cells, e.g., human, monkey, mouse and chinese hamster ovary (CHO) cells, because they provide post-translational modifications to protein molecules including correct folding or glycosylation at correct sites. Also yeast cells can carry out post-translational peptide modifications including glycosylation.
  • Yeast recognizes leader sequences on cloned mammalian gene products and secretes peptides bearing leader sequences (i.e., pre-peptides).
  • the host cells After the introduction of the vector, the host cells are grown in a selective medium, which selects for the growth of vector-containing cells. Expression of the cloned gene sequence(s) results in the production of the desired multimers of the soluble forms of the TNF-Rs.
  • Purification of the recombinant proteins is carried out using monoclonal antibodies to the soluble forms of the TNF-Rs, or by affinity purification on ligand (TNF) columns.
EP92113463A 1991-08-07 1992-08-07 Multimères des formes solubles des récepteurs TNF, leurs préparation et compositions pharmaceutiques les contenant Expired - Lifetime EP0526905B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL99120 1991-08-07
IL99120A IL99120A0 (en) 1991-08-07 1991-08-07 Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them

Publications (3)

Publication Number Publication Date
EP0526905A2 true EP0526905A2 (fr) 1993-02-10
EP0526905A3 EP0526905A3 (en) 1993-05-05
EP0526905B1 EP0526905B1 (fr) 2004-05-12

Family

ID=11062796

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92113463A Expired - Lifetime EP0526905B1 (fr) 1991-08-07 1992-08-07 Multimères des formes solubles des récepteurs TNF, leurs préparation et compositions pharmaceutiques les contenant

Country Status (12)

Country Link
US (1) US5478925A (fr)
EP (1) EP0526905B1 (fr)
JP (1) JPH07145068A (fr)
AT (1) ATE266724T1 (fr)
AU (1) AU661008B2 (fr)
CA (1) CA2075358C (fr)
DE (1) DE69233351T2 (fr)
DK (1) DK0526905T3 (fr)
ES (1) ES2218518T3 (fr)
IL (1) IL99120A0 (fr)
PT (1) PT526905E (fr)
ZA (1) ZA925904B (fr)

Cited By (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0512528A2 (fr) * 1991-05-07 1992-11-11 Yeda Research And Development Company, Ltd. Préparations pharmaceutiques contenant une anticytokine
EP0670730A1 (fr) * 1992-03-30 1995-09-13 Immunex Corporation Proteines de fusion comprenant un recepteur de facteur de necrose tumorale
US5512544A (en) * 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
EP0732938A1 (fr) * 1993-12-01 1996-09-25 Unisearch Limited Procede pour traiter des troubles intestinaux
US5597899A (en) * 1993-03-29 1997-01-28 Hoffmann-La Roche Inc. Tumor necrosis factor muteins
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
EP0812331A1 (fr) 1995-02-28 1997-12-17 The Board Of Trustees Of The Leland Stanford Junior University Complexes antigenes/mhc pour detecter et purifier les lymphocytes t specifiques aux antigenes
US5712381A (en) * 1994-10-19 1998-01-27 Genetics Institute, Inc. MADD, a TNF receptor death domain ligand protein
WO1998049305A1 (fr) * 1997-05-01 1998-11-05 Amgen Inc. Polypeptides opg chimeres
US5847099A (en) * 1994-10-19 1998-12-08 Genetics Institute, Inc. TNF receptor death domain ligand proteins
US5849501A (en) * 1994-10-19 1998-12-15 Genetics Institute, Inc. TNF receptor death domain ligand proteins and method to identify inhibitors of ligand binding
US5852173A (en) * 1994-10-19 1998-12-22 Genetics Institute, Inc. TNF receptor death ligand proteins and inhibitors of ligand binding
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
WO2001025277A1 (fr) * 1999-10-07 2001-04-12 Maxygen Aps Polypeptides antagonistes a chaine unique
US6235281B1 (en) * 1994-02-07 2001-05-22 Knoll Aktiengesellschaft Use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6
US6271346B1 (en) 1989-04-21 2001-08-07 Amgen Inc. TNF Receptors, TNF binding proteins and DNAs coding for them
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US6287558B1 (en) 1997-08-01 2001-09-11 Biohybrio Technologies Llc Devices containing cells or tissue and an agent that inhibits damage by a host cell molecule
US6306820B1 (en) 1996-12-06 2001-10-23 Amgen Inc. Combination therapy using a TNF binding protein for treating TNF-mediated diseases
US6541610B1 (en) 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US6541620B1 (en) 1989-07-18 2003-04-01 Angen Inc. Nucleic acids encoding TNF inhibitor and method of production
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6855808B2 (en) 1995-02-20 2005-02-15 Sankyo Co., Ltd. Proteins and methods for producing the proteins
US6893838B1 (en) 1998-04-07 2005-05-17 Genetics Institute Llc DADD, death activator death domain protein
US6989147B2 (en) 1996-07-09 2006-01-24 Amgen Inc. Truncated soluble tumor necrosis factor type-I and type-II receptors
US7070783B1 (en) 1995-05-09 2006-07-04 The Mathilda And Terence Kennedy Institute Of Rheumatology Small molecular weight TNF receptor multimeric molecule
US7128908B2 (en) 1991-03-18 2006-10-31 Centocor, Inc. Methods for treating systemic lupus erythematosus using anti-TNF antibodies and fragments thereof
US7144987B1 (en) 2000-03-02 2006-12-05 Xencor Protein based tumor necrosis factor-receptor variants for the treatment of TNF related disorders
US7192718B2 (en) 1997-04-15 2007-03-20 Sankyo Co. Ltd Methods for identifying a substance which specifically binds to an osteoclastogenesis inhibitory factor-binding molecule and modulates the biological activity thereof
US7238776B2 (en) 1989-04-21 2007-07-03 Amgen Inc. TNF binding proteins
US7250165B2 (en) 2000-08-07 2007-07-31 Centocor, Inc. Anti-TNF antibodies, compositions, methods and uses
WO2008054603A2 (fr) 2006-10-02 2008-05-08 Amgen Inc. Protéines de liaison à l'antigène du récepteur a de l'il-17
US7411050B2 (en) 1996-12-23 2008-08-12 Immunex Corporation Monoclonal blocking antibody to human RANKL
EP1992636A2 (fr) 1999-11-12 2008-11-19 Amgen Inc. Procédé pour la correction d'un mauvais repliement de bisulfure dans les molécules Fc
EP2002846A2 (fr) 1996-12-06 2008-12-17 Amgen Inc. Thérapie combinée utilisant un inhibiteur IL-1 pour traiter les maladies liées au IL-1
EP2087908A1 (fr) 2001-06-26 2009-08-12 Amgen, Inc. Anticorps opgl
US7718776B2 (en) 2002-04-05 2010-05-18 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
US7722886B2 (en) 2003-05-20 2010-05-25 Wyeth Compositions and methods for treatment of severe acute respiratory syndrome (SARS)
US7807795B2 (en) 1997-04-16 2010-10-05 Amgen Inc. Antibodies to osteoprotegerin binding proteins
US7815909B2 (en) 2000-08-07 2010-10-19 Centocor, Inc. Anti-TNF antibodies, compositions, methods and uses
US7923008B2 (en) 1997-04-16 2011-04-12 Amgen Inc. Methods for decreasing osteoclast formation or bone resorption using an antibody to osteoprotegerin binding protein
US7928074B2 (en) 2002-12-30 2011-04-19 Amgen Inc. Combination therapy with co-stimulatory factors
WO2011046958A1 (fr) 2009-10-12 2011-04-21 Amgen Inc. Utilisation des proteines se liant a un antigene du recepteur a de l'il-17
US8063182B1 (en) 1989-09-12 2011-11-22 Hoffman-Laroche Inc. Human TNF receptor fusion protein
WO2013016220A1 (fr) 2011-07-22 2013-01-31 Amgen Inc. Récepteur a de il-il-17 requis pour biologie il-17c
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
WO2015153144A1 (fr) 2014-03-31 2015-10-08 Kirin-Amgen, Inc. Procédés de traitement du psoriasis des ongles et du cuir chevelu
US10072085B2 (en) 2010-01-15 2018-09-11 Kirin-Amgen, Inc. Method of treating psoriasis using an IL-17 receptor antibody formulation
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
US11014982B2 (en) 2017-02-07 2021-05-25 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
US11041020B2 (en) 2017-01-30 2021-06-22 Janssen Biotech, Inc. Methods for the treatment of active Psoriatic Arthritis
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7011834B1 (en) * 1987-01-30 2006-03-14 The Board Of Trustees Of Leland Stanford Junior University Immunomodulating dimers
US6479632B1 (en) 1988-09-12 2002-11-12 Yeda Research And Development Co. Ltd. Tumor necrosis factor inhibitory protein and its purification
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US5945397A (en) * 1989-09-05 1999-08-31 Immunex Corporation Purified p75 (type II) tumor necrosis factor receptor polypeptides
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US20050260201A1 (en) * 1993-01-29 2005-11-24 Centocor, Inc. Methods of treating rheumatoid arthritis using anti-TNF receptor fusion proteins
US7597886B2 (en) * 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7820798B2 (en) * 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
IL112834A (en) * 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
EA002474B1 (ru) * 1996-02-20 2002-06-27 Апплайд Резеч Системз Арс Холдинг Н.В. Гибридный белок, образующий гетеродимеры, способ его получения и использования
EP1557432B1 (fr) 1996-02-20 2013-08-21 Merck Serono SA Protéines hybrides formant des hétérodimères
US7357927B2 (en) * 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033904A1 (fr) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Recepteurs contenant un domaine de mort cellulaire
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
AU2213697A (en) * 1996-03-18 1997-10-10 Medical Science Systems, Inc. A method for periodontal disease treatment
US6455040B1 (en) 1997-01-14 2002-09-24 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
US8329179B2 (en) * 1997-01-28 2012-12-11 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
ATE362982T1 (de) * 1997-01-28 2007-06-15 Human Genome Sciences Inc ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET
US6433147B1 (en) 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
US7452538B2 (en) 1997-01-28 2008-11-18 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US20040136951A1 (en) * 1997-03-17 2004-07-15 Human Genome Sciences, Inc. Death domain containing receptor 5
US20080248046A1 (en) * 1997-03-17 2008-10-09 Human Genome Sciences, Inc. Death domain containing receptor 5
US20050233958A1 (en) * 1997-03-17 2005-10-20 Human Genome Sciences, Inc. Death domain containing receptor 5
CN1624128A (zh) * 1997-03-17 2005-06-08 人类基因组科学公司 包含死亡结构域的受体－5
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US6187564B1 (en) * 1997-07-10 2001-02-13 Beth Israel Deaconess Medical Center DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
US7704944B2 (en) * 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
AU3072799A (en) 1998-03-19 1999-10-11 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2000050620A2 (fr) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Endokine alpha humain et methodes d'utilisation
KR20070112295A (ko) * 1999-09-10 2007-11-22 제론 코포레이션 올리고뉴클레오티드 엔3'→피5' 티오포스포라미데이트,이의 합성 및 용도
US7662367B2 (en) * 2000-03-02 2010-02-16 Xencor, Inc. Pharmaceutical compositions for the treatment of TNF-α related disorders
US7446174B2 (en) 2001-03-02 2008-11-04 Xencor, Inc. Protein based TNF-α variants for the treatment of TNF-α related disorders
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
US7056695B2 (en) 2000-03-02 2006-06-06 Xencor TNF-α variants
US7687461B2 (en) * 2000-03-02 2010-03-30 Xencor, Inc. Treatment of TNF-α related disorders with TNF-α variant proteins
US7244823B2 (en) * 2000-03-02 2007-07-17 Xencor TNF-alpha variants proteins for the treatment of TNF-alpha related disorders
US20070172449A1 (en) * 2000-03-02 2007-07-26 Xencor, Inc. TNF-alpha VARIANT FORMULATIONS FOR THE TREATMENT OF TNF-alpha RELATED DISORDERS
WO2001096528A2 (fr) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Facteur de necrose tumorale humain delta et epsilon
NZ522700A (en) 2000-06-16 2006-02-24 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
EP1683865A3 (fr) 2001-02-02 2006-10-25 Eli Lilly & Company Protéines de mammifères en particulier CD200
JP2005503116A (ja) 2001-02-09 2005-02-03 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド ヒトｇタンパク質ケモカインレセプター（ｃｃｒ５）ｈｄｇｎｒ１０
CA2444632A1 (fr) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Facteur de croissance 2, endothelial, vasculaire
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) * 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
NZ529359A (en) 2001-05-25 2007-04-27 Human Genome Sciences Inc Antibodies that immunospecifically bind to a TR4 polypeptide or polypeptide fragment or variant of TR4 and their use in a medicament for treating cancer
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US6867189B2 (en) * 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
NZ532881A (en) * 2001-12-20 2008-04-30 Human Genome Sciences Inc Antibodies that immunospecifically bind to trail receptors
AU2003218456A1 (en) * 2002-04-01 2003-10-20 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
WO2004065551A2 (fr) 2003-01-21 2004-08-05 Bristol-Myers Squibb Company Polynucleotides codant une nouvelle co-enzyme d'acyle a, monoacylglycerol acyltransferase-2 (mgat2), et utilisations de ceux-ci
EP1590458B1 (fr) 2003-02-06 2012-10-31 Queen's University Of Belfast Peptide antagoniste du recepteur b2 a la bradykinine provenant de peau d'amphibien
US7553810B2 (en) 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
US7608579B2 (en) 2004-06-16 2009-10-27 Pneumrx, Inc. Lung volume reduction using glue compositions
US20050281799A1 (en) 2004-06-16 2005-12-22 Glen Gong Targeting damaged lung tissue using compositions
US7678767B2 (en) 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
US20050281740A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue
EP1781182B1 (fr) 2004-07-08 2019-11-13 PneumRx, Inc. Dispositif pour le traitement d'epanchement pleural
WO2007008604A2 (fr) * 2005-07-08 2007-01-18 Bristol-Myers Squibb Company Polymorphismes de nucleotides simples associes a l'oedeme dose-dependant, et leurs procedes d'utilisation
US20070202512A1 (en) * 2005-08-19 2007-08-30 Bristol-Myers Squibb Company Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
WO2007142667A2 (fr) 2005-10-13 2007-12-13 Human Genome Sciences, Inc. Procédés et compositions destinées au traitement de patients atteints de maladies positives pour des auto-anticorps
GB0611405D0 (en) * 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
US20100004157A1 (en) * 2006-09-12 2010-01-07 Cosmo Technologies Ltd. Pharmaceutical compositions for the oral or rectal administration of protein substances
WO2008143713A2 (fr) * 2006-12-22 2008-11-27 Dow Agrosciences Llc Vaccins contre le virus du nil occidental (wnv) à base de plante, vecteurs et séquences optimisées de codons végétaux
US20080293053A1 (en) * 2006-12-28 2008-11-27 The Regents Of The University Of Michigan shRNA Materials and Methods of Using Same for Inhibition of DKK-1
US9272048B2 (en) 2008-04-29 2016-03-01 Ascendis Pharma Growth Disorders Division A/S PEGylated recombinant human growth hormone compounds
ES2667025T3 (es) 2009-12-15 2018-05-09 Ascendis Pharma Endocrinology Division A/S Composición seca de hormona de crecimiento unida transitoriamente a un portador de polímero
CA2793838C (fr) 2010-03-19 2019-09-17 H. Lee Moffitt Cancer Center & Research Institute, Inc. Inhibiteurs des interactions de l'integrine pour traiter le cancer
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
EP2552947A4 (fr) 2010-03-26 2013-11-13 Dartmouth College Vista, une protéine médiatrice régulatrice des lymphocytes t, agents de liaison à vista et utilisation associée
CN102219860B (zh) 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
CN102219859B (zh) 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 拮抗血管新生诱导因子的融合蛋白及其用途
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
AU2013312211B2 (en) 2012-09-07 2018-03-29 King's College London VISTA modulators for diagnosis and treatment of cancer
WO2015097536A2 (fr) 2013-12-24 2015-07-02 Janssen Pharmaceutical Nv Anticorps et fragments anti-vista
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
AU2015274504B2 (en) 2014-06-11 2021-02-04 Kathy A. Green Use of VISTA agonists and antagonists to suppress or enhance humoral immunity
US11111284B2 (en) 2014-08-21 2021-09-07 The General Hospital Corporation Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing
AU2015357463B2 (en) * 2014-12-05 2021-10-07 Immunext, Inc. Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
BR112017027870A2 (pt) 2015-06-24 2018-08-28 Janssen Pharmaceutica Nv anticorpos e fragmentos anti-vista
RU2740672C2 (ru) 2015-08-07 2021-01-19 ЭйЭлЭкс Онколоджи Инк. Конструкции, имеющие sirp-альфа домен или его вариант
BR102016018074A2 (pt) 2015-08-07 2021-11-16 ALX Oncology Inc. Construção variante de sirp-alfa, seu método de preparação e seus usos, molécula de ácido nucleico, vetor, célula hospedeira, e composição farmacêutica
US10899836B2 (en) 2016-02-12 2021-01-26 Janssen Pharmaceutica Nv Method of identifying anti-VISTA antibodies
CA3020848A1 (fr) 2016-04-15 2017-10-19 Janssen Pharmaceuticals, Inc. Anticorps anti-vista humain et leur utilisation
BR112021003275A2 (pt) 2018-12-07 2021-06-22 Remegen Co., Ltd. inibidor de angiogênese bifuncional e uso do mesmo
WO2020243338A1 (fr) 2019-05-31 2020-12-03 ALX Oncology Inc. Méthodes de traitement du cancer avec une protéine de fusion sirpalpha-fc en association avec un inhibiteur de point de contrôle immunitaire

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0418014A1 (fr) * 1989-09-11 1991-03-20 Immunex Corporation Récepteurs pour le facteur de nécrose de tumeur alpha et beta
EP0308378B1 (fr) * 1987-09-13 1994-11-30 Yeda Research And Development Company Limited Protéine inhibitrice du facteur de nécrose de tumeur et sa purification
EP0398327B1 (fr) * 1989-05-18 1995-03-15 Yeda Research And Development Company Limited Protéine de liaison II au facteur de nécrose tumorale, sa purification et anticorps spécifiques

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73883A (en) * 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU642938B2 (en) * 1989-12-13 1993-11-04 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein 1 (TBP-1)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0308378B1 (fr) * 1987-09-13 1994-11-30 Yeda Research And Development Company Limited Protéine inhibitrice du facteur de nécrose de tumeur et sa purification
EP0398327B1 (fr) * 1989-05-18 1995-03-15 Yeda Research And Development Company Limited Protéine de liaison II au facteur de nécrose tumorale, sa purification et anticorps spécifiques
EP0418014A1 (fr) * 1989-09-11 1991-03-20 Immunex Corporation Récepteurs pour le facteur de nécrose de tumeur alpha et beta

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FRÈRE, J.M. ET AL. 'Les méthodes de purification et d'analyse des protéines' 1981 , MASSON, PARIS , FRANCE *

Cited By (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512544A (en) * 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
US6417158B1 (en) * 1989-04-21 2002-07-09 Amgen, Inc. Method of ameliorating the harmful effects of TNF using a polypeptide having the ability to bind to TNF
US7282483B2 (en) 1989-04-21 2007-10-16 Amgen Inc. Method of ameliorating the harmful effects of TNF using a polypeptide having the ability to bind to TNF
US7238776B2 (en) 1989-04-21 2007-07-03 Amgen Inc. TNF binding proteins
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6440693B1 (en) 1989-04-21 2002-08-27 Rudolf Hauptmann TNF receptors, TNF binding proteins and DNAS coding for them
US6294352B1 (en) * 1989-04-21 2001-09-25 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6271346B1 (en) 1989-04-21 2001-08-07 Amgen Inc. TNF Receptors, TNF binding proteins and DNAs coding for them
US6541620B1 (en) 1989-07-18 2003-04-01 Angen Inc. Nucleic acids encoding TNF inhibitor and method of production
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
US6541610B1 (en) 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US8163522B1 (en) 1989-09-12 2012-04-24 Hoffman-Laroche Inc. Human TNF receptor
US8063182B1 (en) 1989-09-12 2011-11-22 Hoffman-Laroche Inc. Human TNF receptor fusion protein
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6790444B2 (en) 1991-03-18 2004-09-14 New York University Medical Center Anti-TNF antibodies and peptides of human necrosis factor
US7335358B2 (en) 1991-03-18 2008-02-26 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US7252823B2 (en) 1991-03-18 2007-08-07 Centocor, Inc. Recombinant A2-specific TNFα-specific antibodies
US7276239B2 (en) 1991-03-18 2007-10-02 Centocor, Inc. Recombinant A2-specific TNFα-specific antibodies
US7744885B2 (en) 1991-03-18 2010-06-29 Centocor, Inc. Methods of treating vascular inflammatory pathology using anti-TNF antibodies and fragments thereof
US7227003B2 (en) 1991-03-18 2007-06-05 New York University Anti-TNF antibody fragments
US7226593B2 (en) 1991-03-18 2007-06-05 Centocor, Inc. Methods of treating cachexia with chimeric anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US7223396B2 (en) 1991-03-18 2007-05-29 Centocor, Inc. Methods of treatment of fistulas in Crohn's disease with anti-TNF antibodies
US7214376B2 (en) 1991-03-18 2007-05-08 New York University Methods of inhibiting TNFα in patients with neoplastic disease
US7425330B2 (en) 1991-03-18 2008-09-16 Centocor, Inc. Methods of inhibiting TNFα activity in the blood of a patient
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US7204985B2 (en) 1991-03-18 2007-04-17 Centocor, Inc. Methods of treating disseminated intravascular coagulation by multiple administration of anti-TNF antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US7179466B2 (en) 1991-03-18 2007-02-20 New York University Methods of treating rheumatoid arthritis by multiple administration of anti-TNF antibodies
US7179893B2 (en) 1991-03-18 2007-02-20 New York University Recombinant anti-TNF-α antibodies
US7416729B2 (en) 1991-03-18 2008-08-26 Centocor, Inc. Methods of treating rheumatoid arthritis with anti-TNF antibodies
US7169386B1 (en) 1991-03-18 2007-01-30 New York University Methods of treating inflammation associated with viral infection with anti-TNF antibodies
US6835823B2 (en) 1991-03-18 2004-12-28 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US7169388B2 (en) 1991-03-18 2007-01-30 New York University Methods of inhibiting TNFα in patients with cancer
US7404955B2 (en) 1991-03-18 2008-07-29 Centocor, Inc. Methods of inhibiting or neutralizing TNFα in patients with tissue injury
US7374761B2 (en) 1991-03-18 2008-05-20 Centocor, Inc. Recombinant A2-specific TNFα-specific antibodies
US6991791B2 (en) 1991-03-18 2006-01-31 New York University School Of Medicine Anti-TNF antibodies and peptides of human tumor necrosis factor
US7070775B2 (en) 1991-03-18 2006-07-04 New York University Recombinant A2-specific TNFα specific antibodies
US7166284B2 (en) 1991-03-18 2007-01-23 New York University Methods of treating joint inflammation with anti-TNF antibodies
US7101674B2 (en) 1991-03-18 2006-09-05 New York University Anti-idiotypic anti-TNF antibodies and related immunoassay methods
US7160542B2 (en) 1991-03-18 2007-01-09 New York University Method of treating psoriasis using human anti-TNF antibodies and fragments
US7128908B2 (en) 1991-03-18 2006-10-31 Centocor, Inc. Methods for treating systemic lupus erythematosus using anti-TNF antibodies and fragments thereof
US7128907B2 (en) 1991-03-18 2006-10-31 Centocor, Inc. Methods of treating crohn's disease with anti-TNF antibodies
US7135178B2 (en) 1991-03-18 2006-11-14 Centocor, Inc. Methods of treating disseminated intravascular coagulation using anti-TNF antibodies
US7135179B2 (en) 1991-03-18 2006-11-14 Centocor, Inc. Methods for treating sarcoidosis using anti-TNF antibodies and fragments thereof
US7138118B2 (en) 1991-03-18 2006-11-21 Centocor, Inc. Methods of treating rheumatoid arthritis with anti-TNF antibodies
US7160543B2 (en) 1991-03-18 2007-01-09 New York University Methods of inhibiting TNF-α in patients with Crohn's disease
US7160995B2 (en) 1991-03-18 2007-01-09 New York University DNA encoding anti-TNF antibodies and peptides
EP0512528A2 (fr) * 1991-05-07 1992-11-11 Yeda Research And Development Company, Ltd. Préparations pharmaceutiques contenant une anticytokine
EP0512528A3 (en) * 1991-05-07 1993-07-21 Yeda Research And Development Company, Ltd. Pharmaceutical compositions comprising an anticytokine
EP0670730A4 (fr) * 1992-03-30 1997-02-26 Immunex Corp Proteines de fusion comprenant un recepteur de facteur de necrose tumorale.
EP0670730A1 (fr) * 1992-03-30 1995-09-13 Immunex Corporation Proteines de fusion comprenant un recepteur de facteur de necrose tumorale
US5597899A (en) * 1993-03-29 1997-01-28 Hoffmann-La Roche Inc. Tumor necrosis factor muteins
EP0732938A1 (fr) * 1993-12-01 1996-09-25 Unisearch Limited Procede pour traiter des troubles intestinaux
EP0732938A4 (fr) * 1993-12-01 1997-03-19 Unisearch Ltd Procede pour traiter des troubles intestinaux
US6235281B1 (en) * 1994-02-07 2001-05-22 Knoll Aktiengesellschaft Use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6
US5852173A (en) * 1994-10-19 1998-12-22 Genetics Institute, Inc. TNF receptor death ligand proteins and inhibitors of ligand binding
US5712381A (en) * 1994-10-19 1998-01-27 Genetics Institute, Inc. MADD, a TNF receptor death domain ligand protein
US5847099A (en) * 1994-10-19 1998-12-08 Genetics Institute, Inc. TNF receptor death domain ligand proteins
US7109307B2 (en) 1994-10-19 2006-09-19 Genetics Institute, Llc TNF receptor death domain ligand proteins and inhibitors of ligand binding
US5849501A (en) * 1994-10-19 1998-12-15 Genetics Institute, Inc. TNF receptor death domain ligand proteins and method to identify inhibitors of ligand binding
US5948638A (en) * 1994-10-19 1999-09-07 Genetics Institute, Inc. TNF receptor death domain ligand proteins
US6855808B2 (en) 1995-02-20 2005-02-15 Sankyo Co., Ltd. Proteins and methods for producing the proteins
US7276344B2 (en) 1995-02-20 2007-10-02 Sankyo Co., Ltd. Methods for using the osteoclastogenesis inhibitory factor (OCIF) protein
US7468268B2 (en) 1995-02-20 2008-12-23 Daiichi Sankyo Co., Ltd. Nucleic acid molecules encoding osteoclastogenesis inhibitory factor proteins
EP0812331B1 (fr) * 1995-02-28 2004-05-26 The Board Of Trustees Of The Leland Stanford Junior University Complexes antigenes/mhc pour detecter et purifier les lymphocytes t specifiques aux antigenes
EP1437366A1 (fr) * 1995-02-28 2004-07-14 The Board Of Trustees Of The Leland Stanford Junior University Complexes antigènes/MHC pour détecter et purifier les lymphocytes T spécifiques aux antigènes
EP0812331A1 (fr) 1995-02-28 1997-12-17 The Board Of Trustees Of The Leland Stanford Junior University Complexes antigenes/mhc pour detecter et purifier les lymphocytes t specifiques aux antigenes
US7070783B1 (en) 1995-05-09 2006-07-04 The Mathilda And Terence Kennedy Institute Of Rheumatology Small molecular weight TNF receptor multimeric molecule
US7732587B2 (en) 1996-07-09 2010-06-08 Amgen Inc. Nucleic acids encoding truncated soluble tumor necrosis factor
US6989147B2 (en) 1996-07-09 2006-01-24 Amgen Inc. Truncated soluble tumor necrosis factor type-I and type-II receptors
EP2002846A2 (fr) 1996-12-06 2008-12-17 Amgen Inc. Thérapie combinée utilisant un inhibiteur IL-1 pour traiter les maladies liées au IL-1
US6306820B1 (en) 1996-12-06 2001-10-23 Amgen Inc. Combination therapy using a TNF binding protein for treating TNF-mediated diseases
US7932375B2 (en) 1996-12-23 2011-04-26 Immunex Corporation Kits for detecting rank nucleic acids
US7744886B2 (en) 1996-12-23 2010-06-29 Immunex Corporation Methods for interfering with rank signaling
US8377690B2 (en) 1996-12-23 2013-02-19 Immunex Corporation Cells and methods for producing blocking antibodies to human RANKL
US7411050B2 (en) 1996-12-23 2008-08-12 Immunex Corporation Monoclonal blocking antibody to human RANKL
US8715683B2 (en) 1996-12-23 2014-05-06 Immunex Corporation RANK ligand polypeptides
US7527790B2 (en) 1997-04-15 2009-05-05 Daiichi Sankyo Company, Limited Methods of reducing bone absorption comprising administering an antibody that binds OBM
US7449185B2 (en) 1997-04-15 2008-11-11 Daiichi Sankyo Company, Limited Antibodies to OCIF-binding molecules
US7192718B2 (en) 1997-04-15 2007-03-20 Sankyo Co. Ltd Methods for identifying a substance which specifically binds to an osteoclastogenesis inhibitory factor-binding molecule and modulates the biological activity thereof
US7923008B2 (en) 1997-04-16 2011-04-12 Amgen Inc. Methods for decreasing osteoclast formation or bone resorption using an antibody to osteoprotegerin binding protein
US7807795B2 (en) 1997-04-16 2010-10-05 Amgen Inc. Antibodies to osteoprotegerin binding proteins
WO1998049305A1 (fr) * 1997-05-01 1998-11-05 Amgen Inc. Polypeptides opg chimeres
US6287558B1 (en) 1997-08-01 2001-09-11 Biohybrio Technologies Llc Devices containing cells or tissue and an agent that inhibits damage by a host cell molecule
US7576178B2 (en) 1998-04-07 2009-08-18 Genetics Institute, Llc DADD, death activator death domain protein
US6893838B1 (en) 1998-04-07 2005-05-17 Genetics Institute Llc DADD, death activator death domain protein
WO2001025277A1 (fr) * 1999-10-07 2001-04-12 Maxygen Aps Polypeptides antagonistes a chaine unique
EP1992636A2 (fr) 1999-11-12 2008-11-19 Amgen Inc. Procédé pour la correction d'un mauvais repliement de bisulfure dans les molécules Fc
US7144987B1 (en) 2000-03-02 2006-12-05 Xencor Protein based tumor necrosis factor-receptor variants for the treatment of TNF related disorders
US7691378B2 (en) 2000-08-07 2010-04-06 Centocor, Inc. Anti-TNF antibodies, compositions, methods and uses
US8241899B2 (en) 2000-08-07 2012-08-14 Centocor, Inc. Anti-TNF antibodies, compositions, methods and uses
US7820169B2 (en) 2000-08-07 2010-10-26 Centocor, Inc. Anti-TNF antibodies, compositions, methods and uses
US9321836B2 (en) 2000-08-07 2016-04-26 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and uses
US9828424B2 (en) 2000-08-07 2017-11-28 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and uses
US7250165B2 (en) 2000-08-07 2007-07-31 Centocor, Inc. Anti-TNF antibodies, compositions, methods and uses
US8603778B2 (en) 2000-08-07 2013-12-10 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and uses
US7815909B2 (en) 2000-08-07 2010-10-19 Centocor, Inc. Anti-TNF antibodies, compositions, methods and uses
US7521206B2 (en) 2000-08-07 2009-04-21 Centocor, Inc. Anti-TNF antibodies, compositions, methods and uses
EP2087908A1 (fr) 2001-06-26 2009-08-12 Amgen, Inc. Anticorps opgl
EP3492100A1 (fr) 2001-06-26 2019-06-05 Amgen Inc. Anticorps pour opgl
US8455629B2 (en) 2002-04-05 2013-06-04 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
US7718776B2 (en) 2002-04-05 2010-05-18 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
US8367063B2 (en) 2002-04-05 2013-02-05 Amgen, Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
US7928074B2 (en) 2002-12-30 2011-04-19 Amgen Inc. Combination therapy with co-stimulatory factors
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
US7722886B2 (en) 2003-05-20 2010-05-25 Wyeth Compositions and methods for treatment of severe acute respiratory syndrome (SARS)
WO2008054603A2 (fr) 2006-10-02 2008-05-08 Amgen Inc. Protéines de liaison à l'antigène du récepteur a de l'il-17
US11180564B2 (en) 2006-10-02 2021-11-23 Amgen K-A, Inc. IL-17 Receptor A antigen binding proteins
EP3165539A1 (fr) 2006-10-02 2017-05-10 Kirin-Amgen, Inc. Protéines se liant à des antigènes a du récepteur il-17
US10208122B2 (en) 2006-10-02 2019-02-19 Amgen K-A, Inc. IL-17 receptor A antigen binding proteins
US11858999B2 (en) 2006-10-02 2024-01-02 Amgen K-A, Inc. IL-17 receptor A antigen binding proteins
US8617894B2 (en) 2008-10-31 2013-12-31 Janssen Biotech, Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
WO2011046958A1 (fr) 2009-10-12 2011-04-21 Amgen Inc. Utilisation des proteines se liant a un antigene du recepteur a de l'il-17
US10072085B2 (en) 2010-01-15 2018-09-11 Kirin-Amgen, Inc. Method of treating psoriasis using an IL-17 receptor antibody formulation
US10808033B2 (en) 2010-01-15 2020-10-20 Amgen K-A, Inc. IL-17 receptor antibody formulation
US11505612B2 (en) 2010-01-15 2022-11-22 Amgen K-A, Inc. Method of treating diseases using an IL-17 receptor antibody formulation
WO2013016220A1 (fr) 2011-07-22 2013-01-31 Amgen Inc. Récepteur a de il-il-17 requis pour biologie il-17c
WO2015153144A1 (fr) 2014-03-31 2015-10-08 Kirin-Amgen, Inc. Procédés de traitement du psoriasis des ongles et du cuir chevelu
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
US11124565B2 (en) 2016-02-05 2021-09-21 Janssen Biotech, Inc. Method for treating pre-type 1 diabetes in a human subject
US11041020B2 (en) 2017-01-30 2021-06-22 Janssen Biotech, Inc. Methods for the treatment of active Psoriatic Arthritis
US11014982B2 (en) 2017-02-07 2021-05-25 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha

Also Published As

Publication number Publication date
AU661008B2 (en) 1995-07-13
IL99120A0 (en) 1992-07-15
EP0526905A3 (en) 1993-05-05
DE69233351T2 (de) 2005-05-04
EP0526905B1 (fr) 2004-05-12
ZA925904B (en) 1993-03-25
US5478925A (en) 1995-12-26
DE69233351D1 (de) 2004-06-17
DK0526905T3 (da) 2004-08-16
ES2218518T3 (es) 2004-11-16
JPH07145068A (ja) 1995-06-06
CA2075358C (fr) 2002-10-01
AU2090992A (en) 1993-02-11
ATE266724T1 (de) 2004-05-15
CA2075358A1 (fr) 1993-02-08
PT526905E (pt) 2004-09-30

Similar Documents

Publication Publication Date Title
EP0526905B1 (fr) Multimères des formes solubles des récepteurs TNF, leurs préparation et compositions pharmaceutiques les contenant
US6395267B1 (en) TNF receptor action modulation
AU703919B2 (en) Modulator of TNF/NGF superfamily receptors and soluble oligomeric TNF/NGF superfamily receptors
EP0308378B2 (fr) Protéine inhibitrice du facteur de nécrose de tumeur et sa purification
EP0585939B2 (fr) Ligands du TNF
US5221789A (en) Interferon-gamma receptor fragment and its production
US20070232520A1 (en) Modulator of tnf/ngf superfamily receptors and soluble oligomeric tnf/ngf superfamily receptors
EP0679717B1 (fr) Récepteur de l'interférone soluble, sa préparation et son usage
US5925548A (en) Modified receptors that continuously signal
EP0588177A2 (fr) Protéine se liant à l'interferon-alpha/beta, sa préparation et les compositions pharmaceutiques la contenant
AU714907B2 (en) Modulator of TNF/NGF superfamily receptors and soluble oligomeric TNF/NGF superfamily receptors
IL90339A (en) Anti-cytotoxic protein and its purification
IL103051A (en) Molecules binding to the p75 tnf receptor, their preparation and pharmaceutical compositions containing them
CA2470670A1 (fr) Ligands du tnf
IL103052A (en) Soluble interferon-alpha receptors,their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17P Request for examination filed

Effective date: 19930616

17Q First examination report despatched

Effective date: 19980626

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12N 15/12 A

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WALLACH, DAVID

Inventor name: BRAKEBUSCH, CORD

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69233351

Country of ref document: DE

Date of ref document: 20040617

Kind code of ref document: P

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20040402262

Country of ref document: GR

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: MOINAS & SAVOYE SA

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20040727

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2218518

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20050215

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20110825

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20110810

Year of fee payment: 20

Ref country code: MC

Payment date: 20110726

Year of fee payment: 20

Ref country code: IE

Payment date: 20110810

Year of fee payment: 20

Ref country code: CH

Payment date: 20110812

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20110803

Year of fee payment: 20

Ref country code: ES

Payment date: 20110915

Year of fee payment: 20

Ref country code: FR

Payment date: 20110818

Year of fee payment: 20

Ref country code: GR

Payment date: 20110718

Year of fee payment: 20

Ref country code: DE

Payment date: 20110803

Year of fee payment: 20

Ref country code: AT

Payment date: 20110726

Year of fee payment: 20

Ref country code: PT

Payment date: 20110808

Year of fee payment: 20

Ref country code: SE

Payment date: 20110811

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20110811

Year of fee payment: 20

Ref country code: NL

Payment date: 20110818

Year of fee payment: 20

Ref country code: BE

Payment date: 20110812

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69233351

Country of ref document: DE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69233351

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

Ref country code: NL

Ref legal event code: V4

Effective date: 20120807

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20120807

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20120806

BE20 Be: patent expired

Owner name: *YEDA RESEARCH AND DEVELOPMENT CO. LTD

Effective date: 20120807

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 266724

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120807

REG Reference to a national code

Ref country code: GR

Ref legal event code: MA

Ref document number: 20040402262

Country of ref document: GR

Effective date: 20120808

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20120806

Ref country code: DE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20120808

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20120816

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20130718

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20120808

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20120807